RecruitingNCT04723095
Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix
Sponsor
M.D. Anderson Cancer Center
Enrollment
750 participants
Start Date
May 16, 2013
Study Type
OBSERVATIONAL
Conditions
Stage III Cervical Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8Stage IV Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8Stage IVB Cervical Cancer AJCC v8Stage I Cervical Cancer AJCC v8Stage IA Cervical Cancer AJCC v8Stage IA1 Cervical Cancer AJCC v8Stage IA2 Cervical Cancer AJCC v8Stage IB Cervical Cancer AJCC v8Stage IB1 Cervical Cancer AJCC v8Stage IB2 Cervical Cancer AJCC v8Stage II Cervical Cancer AJCC v8Stage IIA Cervical Cancer AJCC v8Stage IIA1 Cervical Cancer AJCC v8Stage IIA2 Cervical Cancer AJCC v8Stage IIB Cervical Cancer AJCC v8Cervical Large Cell Neuroendocrine CarcinomaCervical Neuroendocrine CarcinomaCervical Small Cell CarcinomaCervical Undifferentiated Carcinoma
Summary
This study collects information and data on patients with neuroendocrine cervical cancer. Information from this study may be used to better understand the correlation between clinical data, such as patient characteristics, treatment, and disease outcomes, and overall patient outcomes.
Eligibility
Inclusion Criteria12
- Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes:
- Small cell neuroendocrine carcinoma
- Large cell neuroendocrine carcinoma
- Undifferentiated high-grade neuroendocrine carcinoma
- Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study
- Patients with all stages of disease are considered eligible
- Patients who do not speak English can be eligible if accompanied by an institutional interpreter
- Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible
- Patient may be residents of any country and be of any ethnic background
- Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website
- Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate
- Next of kin or legal authorized representatives of patients must read and speak English
Exclusion Criteria1
- Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERFollow-Up
Receive follow up
OTHERMedical Chart Review
Review of medical records
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04723095
Related Trials
Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
NCT072763601 location
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
NCT063496423 locations
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT052693811 location
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
NCT039684062 locations
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
NCT072593041 location